BR112018007422A2 - anticorpos anti-age e métodos de uso dos mesmos - Google Patents
anticorpos anti-age e métodos de uso dos mesmosInfo
- Publication number
- BR112018007422A2 BR112018007422A2 BR112018007422A BR112018007422A BR112018007422A2 BR 112018007422 A2 BR112018007422 A2 BR 112018007422A2 BR 112018007422 A BR112018007422 A BR 112018007422A BR 112018007422 A BR112018007422 A BR 112018007422A BR 112018007422 A2 BR112018007422 A2 BR 112018007422A2
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- sequence identity
- onset
- prevent
- delay
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
um anticorpo anti-age compreende uma proteína ou peptídeo que compreende pelo menos uma sequência de aminoácidos com pelo menos 90% de identidade de sequência, preferivelmente pelo menos 95% de identidade de sequência, mais preferencialmente pelo menos 98% de identidade de sequência, com sequências de aminoácidos específicas. o anticorpo anti-age se liga a uma proteína ou peptídeo que exibe uma modificação de carboximetil-lisina. o anticorpo anti-age pode ser usado para matar células senescentes, matar células parcialmente funcionais ou não funcionais, tratar sarcopenia, promover regeneração de tecidos ou tecidos, promover processos regenerativos ou superar efeitos do envelhecimento, tratar aterosclerose, prevenir ou retardar o aparecimento de catarata, prevenir ou retardar o aparecimento de perda de tecido adiposo, aumentar o tempo de saúde, prevenir ou retardar o aparecimento de lordo-cifose, tratar de inflamação ou distúrbios autoimunes, tratar distúrbios neurodegenerativos ou tratar câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241007P | 2015-10-13 | 2015-10-13 | |
US14/974,561 US10358502B2 (en) | 2014-12-18 | 2015-12-18 | Product and method for treating sarcopenia |
PCT/US2016/034880 WO2017065837A1 (en) | 2015-10-13 | 2016-05-27 | Anti-age antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018007422A2 true BR112018007422A2 (pt) | 2018-10-30 |
Family
ID=58518256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018007422A BR112018007422A2 (pt) | 2015-10-13 | 2016-05-27 | anticorpos anti-age e métodos de uso dos mesmos |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3362483A1 (pt) |
JP (1) | JP2018535953A (pt) |
KR (1) | KR20180056689A (pt) |
CN (1) | CN108431044A (pt) |
AU (1) | AU2016336959A1 (pt) |
BR (1) | BR112018007422A2 (pt) |
CA (1) | CA3000815C (pt) |
IL (1) | IL258397A (pt) |
MA (1) | MA42979A (pt) |
MX (1) | MX2018004545A (pt) |
RU (1) | RU2766209C2 (pt) |
WO (1) | WO2017065837A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2499395T3 (es) | 2008-05-23 | 2014-09-29 | Siwa Corporation | Procedimientos para facilitar la regeneración |
EP3511017A1 (en) | 2010-09-27 | 2019-07-17 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
ES2908203T3 (es) | 2014-09-19 | 2022-04-28 | Siwa Corp | Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
KR20230074837A (ko) * | 2016-02-19 | 2023-05-31 | 시와 코퍼레이션 | 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물 |
KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
JP2020516648A (ja) * | 2017-04-13 | 2020-06-11 | シワ コーポレーション | ヒト化モノクローナル終末糖化産物抗体 |
JP2020521117A (ja) * | 2017-05-04 | 2020-07-16 | シワ コーポレーション | 診断用終末糖化産物抗体 |
JP6994876B2 (ja) * | 2017-09-05 | 2022-01-14 | 株式会社エッグ | 計測器 |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
WO2019183282A1 (en) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Senolytic agents for the treatment of tauopathies |
US20220175916A1 (en) * | 2018-07-23 | 2022-06-09 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
US20210253739A1 (en) * | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
CN114957470B (zh) * | 2021-11-12 | 2023-01-17 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
WO2023177390A1 (en) * | 2022-03-14 | 2023-09-21 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
BR122014028365B8 (pt) * | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
JP4012722B2 (ja) * | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
EP1988918A4 (en) | 2006-02-22 | 2010-04-28 | Novavax Inc | ADJUVANZ AND VACCINE COMPOSITIONS |
ES2499395T3 (es) | 2008-05-23 | 2014-09-29 | Siwa Corporation | Procedimientos para facilitar la regeneración |
-
2016
- 2016-05-27 CA CA3000815A patent/CA3000815C/en active Active
- 2016-05-27 EP EP16731696.7A patent/EP3362483A1/en not_active Withdrawn
- 2016-05-27 JP JP2018519727A patent/JP2018535953A/ja active Pending
- 2016-05-27 AU AU2016336959A patent/AU2016336959A1/en not_active Abandoned
- 2016-05-27 CN CN201680059997.5A patent/CN108431044A/zh active Pending
- 2016-05-27 WO PCT/US2016/034880 patent/WO2017065837A1/en active Application Filing
- 2016-05-27 MA MA042979A patent/MA42979A/fr unknown
- 2016-05-27 MX MX2018004545A patent/MX2018004545A/es unknown
- 2016-05-27 BR BR112018007422A patent/BR112018007422A2/pt not_active Application Discontinuation
- 2016-05-27 KR KR1020187010762A patent/KR20180056689A/ko not_active Application Discontinuation
- 2016-05-27 RU RU2018110885A patent/RU2766209C2/ru active
-
2018
- 2018-03-27 IL IL258397A patent/IL258397A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2018004545A (es) | 2018-08-01 |
KR20180056689A (ko) | 2018-05-29 |
AU2016336959A1 (en) | 2018-04-12 |
WO2017065837A1 (en) | 2017-04-20 |
IL258397A (en) | 2018-05-31 |
JP2018535953A (ja) | 2018-12-06 |
RU2766209C2 (ru) | 2022-02-09 |
RU2018110885A (ru) | 2019-11-19 |
EP3362483A1 (en) | 2018-08-22 |
RU2018110885A3 (pt) | 2020-01-30 |
CA3000815C (en) | 2022-11-01 |
MA42979A (fr) | 2021-05-26 |
CN108431044A (zh) | 2018-08-21 |
CA3000815A1 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018007422A2 (pt) | anticorpos anti-age e métodos de uso dos mesmos | |
CL2017003132A1 (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
EA201591467A1 (ru) | Анти-lag-3 связывающие белки | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
MX2017014730A (es) | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). | |
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
EA201501028A1 (ru) | Конструкции митохондриальных белков и их применение | |
EA201890198A1 (ru) | Новые белки, специфичные в отношении lag-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |